A study conducted by a team of researchers have found that lithium in doses up to 400 times lower than what is been prescribed for mood disorders is capable of halting signs of advanced Alzheimer's pathology and recovering of lost cognitive abilities. The study was conducted by McGill researchers' led by Dr. Claudio Cuello of the Department of Pharmacology and Therapeutics has shown that when given in a formulation that facilitates passage to brain lithium prescribed in doses a few times lower than usually given can bring a halt to Alzheimer's disease. The finding is published in the latest edition